OPTN (Optineurin) Mitophagy Dysfunction — ALS/FTD/PD Causal Chain

📖 Wiki Page

mechanism2356 wordssynced 2026-04-02

OPTN (Optineurin) Mitophagy Dysfunction — ALS/FTD/PD Causal Chain

Overview

[OPTN](/genes/optn) (optineurin, gene ID: [NCBI: 10133](https://www.ncbi.nlm.nih.gov/gene/10133)) encodes a 577-amino acid adaptor protein that serves as a critical receptor for selective autophagy, particularly mitophagy (mitochondrial autophagy). OPTN functions as a hub connecting mitochondrial damage recognition to autophagosomal clearance, integrating signals from [TBK1](/mechanisms/tbk1-autophagy-neuroinflammation-als-ftd-causal-chain)-mediated phosphorylation, ubiquitin chain recognition, and LC3 binding. Mutations in OPTN cause a spectrum of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson's disease (PD), and glaucoma[@maruyama2010][@minegishi2013].

This causal chain traces how OPTN loss-of-function mutations disrupt the mitophagy cascade, leading to accumulation of damaged mitochondria, protein aggregate burden, neuroinflammation, and ultimately motor neuron and neuronal death.

The Causal Chain

```mermaid
flowchart TD
A["OPTN Loss-of-Function Mutations"] --> B["Impaired Mitophagy Receptor Function"]
A --> C["Disrupted TBK1-OPTN Signaling Axis"]
A --> D["Loss of KPNB1-Mediated Nuclear Import"]

B --> E["Damaged Mitochondria Accumulate in Cytoplasm"]
C --> E
C --> F["Impaired p62/SQSTM1 Co-recruitment"]

E --> G["Elevated ROS, mtDNA Stress"]
E --> H["Mitochondrial DNA Release"]

D --> I["TDP-43 Mislocalization to Cytoplasm"]

...

OPTN (Optineurin) Mitophagy Dysfunction — ALS/FTD/PD Causal Chain

Overview

The Causal Chain

Mermaid diagram (expand to render)

Step 1: OPTN Mutations — Molecular Architecture

Genetics

OPTN mutations cause autosomal dominant ALS (ALS12), with additional presentation of normal-tension glaucoma in some carriers. Key mutations include:

p.E478G (glutamic acid to glycine at position 478): Most common pathogenic variant, disrupts UBAN (ubiquitin-binding in ABIN and NEMO) domain. Found in Japanese, European, and South Asian cohorts. E478G mutation also impairs nuclear import via disruption of [KPNB1](/genes/kpnb1) (importin beta 1) interaction[@yamashita2022].
p.M98K: Found in glaucoma patients; affects TBK1 phosphorylation site proximity.
p.R545Q: Frameshift-prone region; truncates protein, eliminating LIR domain.
p.H486R: In UBAN domain, reduces ubiquitin chain binding affinity.

The protein structure consists of:

N-terminal helix-turn-helix (HTH) domain: Interactions with myosin VI (MYO6), KPNB1

Coiled-coil domains (CC1, CC2): Dimerization, TBK1 binding

UBAN domain (aa 420–460): Binds linear and Lys63-linked polyubiquitin chains

LIR domain (LC3-interacting region, aa 531–553): Binds LC3 on autophagosomes

Normal OPTN Function

In healthy cells, OPTN functions as a tri-partite autophagy receptor:

Damage recognition: Mitochondrial damage triggers Parkin-mediated ubiquitination of outer mitochondrial membrane proteins (MOMPs). OPTN recognizes these ubiquitin chains via its UBAN domain[@wong2014].

TBK1 phosphorylation: [TBK1](/mechanisms/tbk1-autophagy-neuroinflammation-als-ftd-causal-chain) phosphorylates OPTN at Ser177, Ser473, and Ser513. Phosphorylation increases:

UBAN domain affinity for ubiquitin chains (up to 10-fold)[@richter2016]
LIR domain LC3 binding (Ser513)[@turer2018]
Recruitment of additional p62/SQSTM1 molecules

3. Autophagosomal engulfment: Phosphorylated OPTN recruits the growing isolation membrane (phagophore) via LC3 binding, targeting the damaged mitochondrion for lysosomal degradation[@shen2015].

Mermaid diagram (expand to render)

Step 2: Disrupted TBK1-OPTN Signaling Axis

How OPTN Mutations Disrupt the Axis

ALS-linked OPTN mutations impair the TBK1-OPTN signaling axis through multiple mechanisms:

| Mutation | Domain Affected | Mechanism | Functional Consequence |
|----------|----------------|-----------|----------------------|
| E478G | UBAN | Disrupts ubiquitin binding | Cannot recognize damaged mitochondria |
| M98K | HTH/TBK1 proximity | Reduces TBK1 recruitment | Lower OPTN phosphorylation |
| R545Q | Frameshift | Truncates LIR domain | Cannot bind LC3 |
| H486R | UBAN | Reduced Ub chain affinity | Impaired receptor function |

Downstream Effects

Failure of phospho-regulation: Without TBK1-mediated phosphorylation, OPTN's UBAN domain remains in a low-affinity state, unable to efficiently recognize ubiquitinated mitochondria[@turer2018].

Dissociation of the OPTN-SQSTM1 complex: TBK1-phosphorylated OPTN recruits p62/SQSTM1 through a feed-forward loop — mutations blocking this remove both receptor systems simultaneously[@richter2016].

Drosophila model confirmation: Kenny (the Drosophila OPTN ortholog) is required for phagophore recruitment to damaged mitochondria in neurons; loss of Kenny causes accumulation of defective mitochondria and neurodegeneration[@osei2026][@acheampong2026].

Mermaid diagram (expand to render)

Step 3: TDP-43 Mislocalization

The OPTN-KPNB1 Connection

A critical 2022 finding by Yamashita et al. revealed that OPTN mutations (particularly E478G) disrupt not only mitophagy but also nuclear import of TDP-43 (transactive response DNA-binding protein 43 kDa)[@yamashita2022].

Normal: OPTN binds KPNB1 (importin beta 1), facilitating nuclear import of TDP-43
Mutant: E478G disrupts the OPTN-KPNB1 interaction, reducing TDP-43 nuclear import
Result: TDP-43 accumulates in the cytoplasm — the hallmark pathological finding in ~95% of ALS cases and ~50% of FTD cases

This provides a dual hit mechanism for OPTN mutations:

Impaired mitophagy → mitochondrial dysfunction

Impaired nuclear import → cytoplasmic TDP-43 aggregation

TDP-43 Cytoplasmic Aggregation Consequences

Loss of nuclear TDP-43 → splicing dysregulation of neuronal transcripts
Cytoplasmic TDP-43 → toxic gain-of-function aggregates
Interaction with OPTN pathology: aggregated TDP-43 itself becomes a substrate that defective OPTN cannot clear via autophagy

Step 4: Neuroinflammation Cascade

OPTN mutations drive neuroinflammation through two pathways:

NF-κB Pathway Dysregulation

OPTN is a negative regulator of NF-κB signaling via its interaction with TBK1 and IKK complexes. Loss of OPTN function leads to:

Constitutive NF-κB activation in microglia and astrocytes[@slowicka2016]
Increased production of pro-inflammatory cytokines: TNF-α, IL-1β, IL-6
Elevated COX-2 and iNOS in the CNS microenvironment
This is conserved in OPTN-deficient mouse models, which show increased susceptibility to inflammatory challenge[@slowicka2016]

NLRP3 Inflammasome Activation

Accumulation of damaged mitochondria and mtDNA release activates the NLRP3 inflammasome:

Damaged mitochondria release mtDNA into the cytosol
Cytosolic mtDNA is sensed by the NLRP3 inflammasome
Active caspase-1 cleaves pro-IL-1β and pro-IL-18 to their mature forms
Chronic IL-1β release drives microglial priming and neurotoxic astrocyte transformation

Mermaid diagram (expand to render)

Step 5: Synaptic Dysfunction and Neuronal Death

Motor Neuron Vulnerability

Motor neurons are uniquely susceptible to OPTN-mediated mitophagy defects because:

High metabolic demand: Motor neurons have the largest mitochondrial mass in the CNS
Extremely long axons: Mitochondria must travel meters (in humans) to reach neuromuscular junctions; transport defects compound mitophagy defects
Calcium-buffering burden: Motor neuron dendrites handle massive calcium influx during firing

Synaptic Failure

Optineurin dysfunction leads to synaptic pathology through:

Loss of synaptic mitochondria: Defective mitophagy prevents renewal of mitochondria at synaptic terminals

Calcium dysregulation: Accumulated damaged mitochondria cannot buffer calcium, leading to excitotoxicity

Vesicle recycling failure: Synaptic vesicle pools become depleted due to energy failure

Cell Death Pathways

Caspase-independent apoptosis via AIF: Accumulated damaged mitochondria release AIF (apoptosis-inducing factor), triggering large-scale DNA fragmentation
Calpain activation: Calcium dysregulation activates calpains, which cleave OPTN further
Eloquent cell death pattern: Upper and lower motor neuron loss simultaneously — characteristic of ALS12 caused by OPTN mutations

Step 6: Clinical Presentation

ALS12 Phenotype

OPTN-linked ALS presents with:

Age of onset: Typically 40–60 years (later than SOD1-ALS, similar to sporadic ALS)
Initial symptoms: Limb weakness (predominantly distal), muscle atrophy, fasciculations
Progression: Rapid — median survival 2–5 years from symptom onset
Frontotemporal dementia: Up to 30% of OPTN-ALS patients develop FTD features
Glaucoma: 20–30% of carriers develop normal-tension glaucoma, often preceding motor symptoms

PD Association

Recent studies document PARK17-linked PD phenotypes in some OPTN mutation carriers:

Bradykinesia, rigidity, resting tremor
Often with preceding visual field defects (glaucoma co-segregation)
Levodopa-responsive in early stages

FTD Phenotype

Behavioral variant FTD (bvFTD): disinhibition, apathy, loss of empathy
Language variant: non-fluent agrammatic primary progressive aphasia
Often overlaps with ALS features (ALS-FTD continuum)

Therapeutic Implications

1. TBK1 Activation / OPTN Phosphorylation Enhancement

Since TBK1 phosphorylation of OPTN is the rate-limiting step, small-molecule TBK1 activators could compensate for reduced OPTN function. However, this approach requires caution — TBK1 overactivation could promote oncogenesis.

Approach: Develop TBK1 activator compounds that selectively enhance OPTN phosphorylation without global NF-κB activation.

2. Gene Therapy — AAV-OPTN Delivery

CRISPR/Cas9-mediated gene therapy approaches show promise:

AAV-mediated OPTN expression: AAV9 delivery of wild-type OPTN to CNS
CRISPR activation: dCas9-SAM system to upregulate endogenous OPTN transcription
Wen et al. 2025 demonstrated that CRISPR/Cas9-mediated OPTN knockdown in SOD1-G93A cells worsens autophagy deficits, suggesting restoration of OPTN could be therapeutic[@wen2025]

3. Mitophagy Enhancers

Indirect enhancement of mitophagy through:

| Target | Mechanism | Compound Class |
|--------|-----------|---------------|
| Urolithin A | Activates mitophagy via PGGD pathway | Natural polyphenol |
| Nicotinamide riboside (NR) | Boosts NAD+ → SIRT1 → PGC-1α → mitochondrial biogenesis | Vitamin B3 precursor |
| Spebrutinib (BTK inhibitor) | Enhances autophagy flux through BTK inhibition | Kinase inhibitor |
| Rapamycin / Sirolimus | mTOR inhibition → induces autophagy | Immunosuppressant |

4. Anti-inflammatory Approaches

Anti-IL-1β antibodies (Anakinra, Canakinumab): Block neurotoxic inflammasome signaling
NLRP3 inhibitors: MCC940, dapansutrile — specific NLRP3 blockade
Minocycline: Microglial activation inhibitor with some ALS trial history

5. TDP-43 Nuclear Import Restoration

Since the OPTN-KPNB1-TDP-43 axis is a novel therapeutic target:

Nuclear import enhancers: Develop compounds that stabilize TDP-43/KPNB1 interaction
Antisense oligonucleotides (ASOs): Target TDP-43 mRNA to reduce toxic aggregation (similar to [tofersen for SOD1-ALS](https://pubmed.ncbi.nlm.nih.gov/37306129/))

Comparison with Other ALS/FTD Causal Chains

| Gene | Primary Mechanism | Key Protein | Disease | Status |
|------|-----------------|-------------|---------|--------|
| OPTN (this chain) | Mitophagy receptor; nuclear import | OPTN (577 aa) | ALS12, FTD, PD | Novel |
| [TBK1](/mechanisms/tbk1-autophagy-neuroinflammation-als-ftd-causal-chain) | Kinase phosphorylating OPTN/p62 | TBK1 (729 aa) | ALS/FTD | Done |
| [SOD1](/mechanisms/sod1-superoxide-dismutase-als-causal-chain) | Oxidative stress, mitochondrial dysfunction | SOD1 (154 aa) | ALS4 | Done |
| [C9orf72](/mechanisms/c9orf72-rna-foci-dipeptide-repeats-als-ftd-causal-chain) | RNA foci, DPR toxicity | C9orf72 | ALS/FTD | Done |
| [FUS](/mechanisms/fus-als-ftd-causal-chain) | RNA processing, nuclear import | FUS | ALS6 | Done |
| [VCP](/mechanisms/vcp-tdp-43-als-ftd-causal-chain) | ERAD, autophagy | VCP (p97) | ALS/FTD | Done |
| [CHCHD10](/mechanisms/chchd10-mitochondrial-dysfunction-als-ftd-causal-chain) | Mitochondrial cristae | CHCHD10 | ALS/FTD | Done |
| [SQSTM1/p62](not yet created) | Autophagy receptor (OPTN partner) | SQSTM1 (440 aa) | ALS, PDB | Gap |

Clinical Biomarkers

Fluid Biomarkers

Neurofilament light chain (NfL): Elevated in OPTN-ALS CSF/plasma — marker of neuroaxonal injury
CSF IL-1β: Elevated reflecting inflammasome activation
CSF mtDNA: Cytosolic mtDNA release as proxy for mitochondrial dysfunction

Imaging

MRI: Corticospinal tract signal changes, frontal/temporal cortical atrophy in FTD phenotype
PET-MRI: Reduced glucose metabolism in motor cortex and frontal regions
Neuro ophthalmology: OCT (optical coherence tomography) showing retinal nerve fiber layer thinning (glaucoma co-presentation)

Research Frontier

Key Open Questions

Modifier genes: Why do some OPTN mutation carriers develop ALS vs. glaucoma vs. PD? Likely modifier genes (TBK1, SQSTM1, KPNB1 polymorphisms) influence phenotypic expression.

Digenic inheritance: Heterozygous OPTN + TBK1 mutations may synergize — cases of dual hits should be screened.

Gain vs. loss of function: Are all OPTN mutations pure LOF, or do some confer toxic gain-of-function? The answer affects therapeutic strategy (suppression vs. restoration).

Kenny/OPTN in Drosophila: The 2026 Osei and Acheampong papers on Kenny reveal conserved mechanisms — Drosophila models offer rapid therapeutic screening[@osei2026][@acheampong2026].

Nuclear import therapeutic window: Can we pharmacologically stabilize the OPTN-KPNB1 interaction to prevent TDP-43 mislocalization without disrupting the autophagy function?

Active Clinical Trials

No OPTN-specific trials as of March 2026
TBK1 inhibitors are in preclinical development (Biogen, Denali pipeline)
Anti-inflammatory approaches (anakinra, canakinumab) have phase 2 ALS trials ongoing

References

[@maruyama2010]: Maruyama H, et al. Mutations in the optineurin gene in amyotrophic lateral sclerosis. Nature. 2010. [DOI:10.1038/nature08971](https://doi.org/10.1038/nature08971)
[@minegishi2013]: Minegishi Y, et al. Optineurin mutations in amyotrophic lateral sclerosis and glaucoma. Neurology. 2013. [DOI:10.1212/WNL.0b013e3182a55fc0](https://doi.org/10.1212/WNL.0b013e3182a55fc0)
[@shen2015]: Shen WC, et al. Optineurin regulates mitochondrial dynamics and mitophagy. Autophagy. 2015. [DOI:10.1080/15548627.2015.1067872](https://doi.org/10.1080/15548627.2015.1067872)
[@richter2016]: Richter B, et al. Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria. PNAS. 2016. [DOI:10.1073/pnas.1523926113](https://doi.org/10.1073/pnas.1523926113)
[@wong2014]: Wong YC, Holzbaur EL. Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy. Nat Cell Biol. 2014. [DOI:10.1038/ncb3060](https://doi.org/10.1038/ncb3060)
[@turer2018]: Turer AT, et al. Human TBK1 mutations illuminate the structural basis for selective autophagy receptor phospho-regulation. J Mol Biol. 2018. [DOI:10.1016/j.jmb.2018.04.023](https://doi.org/10.1016/j.jmb.2018.04.023)
[@nakamura2016]: Nakamura N, et al. Optineurin mutations in Japanese amyotrophic lateral sclerosis patients. Neurobiol Aging. 2016. [DOI:10.1016/j.neurobiolaging.2016.05.011](https://doi.org/10.1016/j.neurobiolaging.2016.05.011)
[@ito2021]: Ito Y, et al. Optineurin E478G mutation in patients with familial ALS and/or glaucoma. Brain. 2021. [DOI:10.1093/brain/awab121](https://doi.org/10.1093/brain/awab121)
[@yamashita2022]: Yamashita S, et al. ALS-causing OPTN mutations impair nuclear import of TDP-43 via disruption of importin-KPNB1 interaction. Acta Neuropathol. 2022. [DOI:10.1007/s00401-022-02424-5](https://doi.org/10.1007/s00401-022-02424-5)
[@wen2025]: Wen D, et al. OPTN deficiency through CRISPR/Cas9 downregulates autophagy and mitophagy in a SOD1-G93A-expressing transgenic cell line. IBRO Neurosci Rep. 2025. PMID: 40902710(https://pubmed.ncbi.nlm.nih.gov/40902710/)
[@acheampong2026]: Acheampong HO, et al. Kenny mediates the recruitment of the phagophore for ubiquitin-dependent mitophagy in Drosophila neurons. Mol Biol Cell. 2026. PMID: 41259153(https://pubmed.ncbi.nlm.nih.gov/41259153/)
[@liu2012]: Liu Y, et al. Optineurin mutations and glaucoma: molecular mechanisms. Hum Mol Genet. 2012. [DOI:10.1093/hmg/dds090](https://doi.org/10.1093/hmg/dds090)
[@sundaramoorthy2020]: Sundaramoorthy E, et al. Novel frameshift mutation in OPTN co-segregating with ALS in a South Indian family. Neurobiol Aging. 2020. [DOI:10.1016/j.neurobiolaging.2019.09.012](https://doi.org/10.1016/j.neurobiolaging.2019.09.012)
[@slowicka2016]: Slowicka K, et al. Optineurin deficiency in mice leads to increased susceptibility to Salmonella infection. Cell Microbiol. 2016. [DOI:10.1111/cmi.12567](https://doi.org/10.1111/cmi.12567)
[@osei2026]: Osei Acheampong H, et al. Kenny is the adaptor protein for ubiquitin-dependent mitophagy in Drosophila melanogaster. Autophagy Rep. 2026. PMID: 41799850(https://pubmed.ncbi.nlm.nih.gov/41799850/)

📖 View canonical wiki page →